Docking Study of Quercetin Derivatives on Inducible Nitric Oxide Synthase and Prediction of their Absorption and Distribution Properties
Some flavonoids, including quercetin, were reported to show inhibitory activities against inducible Nitric Oxide Synthase (iNOS), an isoenzyme responsible for nitric oxide formation. The objectives of this research are to obtain binding and inhibitory parameters of some quercetin derivatives on iNOS by means of docking method and prediction of their oral absorption and distribution properties. Seven selected flavonoids and ten quercetin derivatives were used as ligands for the study. The iNOS structure was obtained from Brookhaven protein databank (PDB ID: 1M9T) and docking study was performed using ArgusLab free software. Binding energy (ΔGbind) and hydrogen bond were used to analyze interactions between ligands and active site of iNOS. The PreADMET on line program was used to predict the oral absorption and distribution properties including permeability for Caco-2 cell, HIA (human intestinal absorption) and plasma protein binding. The results showed that hydrogen bonds formed between flavonoids and iNOS always involved the amide groups of glycine (A365) and trypsine (A366) residues in iNOS active site and 4-carbonyl group of flavonoids. In the docked form, the planar region of A-ring of flavonoids oriented to the heme plane of iNOS. Thus the 4-carbonyl group and planar region of A-ring of flavonoids are essential for the binding with iNOS. Linear regression of binding energy versus negative logarithm of IC50 of flavonoids gave an equation of -log IC50 = -0.399 ΔGbind- 5.608 (R2 = 0.686; p<0.01) and predicted IC50 of Quercetin was 76.79 μM. The human intestinal absorption (HIA) and Caco-2 cell permeability values of quercetin were 63.5% and 3.4 nm sec-1 while its plasma protein binding was 93.2%, respectively. Quercetin-3-O-acetate, 6,8-dichloroquercetin-3-O-acetate and 6-bromoquercetin-3-O-acetate showed lower predicted IC50 and better absorption and distribution properties than quercetin.
June 22, 2010; Accepted: September 28, 2010;
Published: October 14, 2010
Nitric Oxide (NO) is produced from L-arginine in mammalian tissue by Nitric
Oxide Synthase (NOS) enzymes. There are three NOS isoenzymes, i.e., nNOS (constitutive
in neuronal tissue), eNOS (constitutive in vascular endothelial cells) and iNOS
(inducible by cytokine in macrophages and hepatocytes) (Knowles
and Moncada, 1994). Constitutively expressed eNOS and nNOS are responsible
for low physiological levels of NO, whereas larger amounts of NO are produced
by iNOS. iNOS is induced by microbial products, such as lipopolysaccharide (LPS)
and inflammatory cytokines such as interleukin-1 (IL-1), tumor necrosis factor-α
(TNF-α) and interferon-γ (INF-γ) in macrophages and some other
cells (Hamalainen et al., 2007). NO production
is increased in respon to inflammatory stimuli and mediates the destructive
effects (Korhonen et al., 2005). Because of the
importance of NO derived from iNOS in inflammation response, there were several
research efforts to find a selective iNOS inhibitor. The compounds inhibiting
expression or activity of iNOS are proposed to be potential as anti-inflammatory
agents (Knowles and Moncada, 1994).
Flavonoids (Fig. 1) are a group of naturally occurring polyphenolic compounds containing two benzene rings linked together with a heterocyclic pyran or pyrone ring and ubiquitously found in fruits and vegetables.
|| General structure of flavonoid
|| Structures and in vitro inhibitory activities of flavonoids
and their predicted binding energy to iNOS
|*IC50 values were taken from Olszanecki
et al. (2002)
Flavonoids have been known to show potential health benefits (Hamalainen
et al., 2007). Some of flavonoids have been reported to have anti-inflammatory
properties by inhibition of iNOS in culture medium of LPS-stimulated, i.e.,
kaempferol, quercetin, apigenin, primuletin, catechin, hesperetin and naringenin
(Table 1) (Olszanecki et al., 2002).
Quercetin (3,3,4,5,7-pentahydroxyflavon) is a flavonoid suitable
to be chosen as the lead compound for development of safe anti-inflammatory
agent, because in addition to its anti-inflammatory effect, quercetin also shows
protective effect in gastrointestinal track (Morikawa et
al., 2003; Coskun et al., 2004). However,
clinical use or clinical using of quercetin was limited by its low oral bioavailability
(Peng et al., 2008). Thus, molecular modification
of quercetin was needed to increase the oral bioavailability and enhance its
Molecular docking is a tool in structural molecular biology and structure-based
drug discovery. The goal of ligand-protein docking is to understand and predict
molecular recognition, finding likely binding modes and predicting binding affinity
(Morris and Lim-Wilby, 2008). ArgusLab 4.0.1. is a freely
available docking software, which serves two docking engine, i.e., GADock and
ArgusDock (ArgusLab, 2004). These engines are capable
for binding free energy calculation between proteins and ligands. Furthermore,
ArgusLab is easy and inexpensive program useful for virtual screening (Oda
and Takahashi, 2009).
Prediction of ADME (absorption, distribution, metabolism and excretion) properties
has been developed to reduce the probability of the failure at the development
stage of drug candidates. PreADMET is a web-based application for predicting
ADME data and building drug-like library using in silico method. This program
is useful for the construction of drug absorption prediction system. In absorption,
it provides prediction models for in vitro Caco-2 -cell and MDCK cell
(Madin-Darby canine kidney) assay as well as in silico HIA (human intestinal
absorption). In distribution, it provides prediction of plasma protein binding
and BBB (blood brain barrier) penetration (Lee et al.,
2003). The objectives of this research are to obtain binding and inhibitory
parameters of some quercetin derivatives on iNOS by means of docking method
and prediction of their oral absorption and distribution properties.
MATERIALS AND METHODS
All research activities were conducted in Laboratory of Drug Design and High Computing, School of Pharmacy ITB, Indonesia.
Structural models: Structure coordinate for iNOS was taken from the
RCSB Protein Data Bank (PDB ID: 1M9T), in which inducible NOS oxygenase domains
was cocrystallized with 3-bromo-7-nitroindazole (Rosenfeld
et al., 2002). The 3D structures of flavonoids and quercetin derivatives
were first constructed using Arguslab 4.0.1., then were optimized using Austin
Model 1 (AM1), 200 maximum iteration, followed by conjugate gradient minimization
to a Root Mean Square (RMS) energy gradient of 0.01 kcal/(mol Å) (ArgusLab
Molecular docking: Structures of both protein and ligand molecule were
extracted from the PDB data and were used in docking tests. After adding the
hydrogen atoms, ligand molecules were minimized using the Universal Force Field
(UFF) implemented in ArgusLab. For the docking tests, both ArgusDock and GADock
were evaluated; then, the results were compared. Default setting of the scoring
function and adjusted functions were used for the study. Furthermore, size of
the binding site bounding box was determined automatically using ArgusLab (16.452x15.215x14.010
Å). Root-Mean-Square Deviation (RMSD) between the experimental and computational
ligand structure were computed to evaluate the accuracy of the calculated poses;
the calculated pose with RMSD that was less than or equal to 2.0 Å was
defined as reasonable poses. The validated method of docking calculation then
used to perform the docking of flavonoids and quercetin derivatives to iNOS
binding site. Binding affinity was characterized by binding energy values (ΔG)
and hydrogen bonds between ligands and the enzyme (Oda et
Predicting the affinities of quercetin derivatives to iNOS: The in
vitro biological activity data reported as IC50 for inhibition
of iNOS by the flavonoids were used for the current study (Olszanecki
et al., 2002). The correlation curve of the binding energies (ΔG,
kcal mol-1) of flavonoids with iNOS to the experimental activities
(-log IC50) was constructed. The obtained regression equation then
was used to calculate the predicted IC50 of quercetin derivatives
(Zheng et al., 2006; Ji
and Zhang, 2006).
Predicting the absorption and distribution properties using PreADMET:
PreADMET program was accessed at
http://preadmet.bmdrc.org/. Chemical structures of the compounds were drawn
or uploaded from Molfile (*.mol). The program automatically calculated the predictive
adsorption and distribution parameter we used, i.e., permeability for Caco-2
cell, HIA (human intestinal absorption) and plasma protein binding (PreADMET,
Accuracy of docking method: Arguslab has two docking engine types, i.e.,
ArgusDock and GADock. In addition, A-score is used as a scoring function. We
compared the accuracy of ArgusDock and GADock, by measuring the Root Mean Square
Deviation (RMSD) of the Cartesian coordinates of the atoms of the ligand (3-bromo-7-nitroindazole)
in the docked and crystallographic conformations. A docking method is generally
regarded as successful if the RMSD value is less than 2Å (Morris
and Lim-Wilby, 2008). In present study, ArgusDock engine was failed to perform
an accurate docking calculation, due to the RMSD value was 5.9067 Å. However,
GADock engine gave a better result. Figure 2 shows the conformational
superposition of 3-bromo-7-nitroindazole from the X-ray crystal structure of
3-bromo-7-nitroindazoleiNOS complex and that from the docking calculation
by GADock engine. RMSD value between the two conformations is only 1.3494 Å,
indicating that the parameter set for docking is capable of reproducing the
X-ray structure. In addition, both of ligand (original ligand and that from
the docking simulation) interact to the same residue of iNOS, i.e., Met368,
so this engine then was used to perform the docking calculation of the flavonoids
and quercetin derivatives.
||Conformational comparison of 3-bromo-7-nitroindazole from
the crystal structure of 3-bromo-7-nitroindazoleiNOS complex (red)
and that from the docking simulation using GADock engine (blue)
||Superimposition of the binding conformations of flavonoids
(green) on the binding site of iNOS. Hydrogen bonds are marked in red lines
||Correlation of predicted binding energy (ΔG, kcal mol-1)
of flavonoids with iNOS to experimental activities (-log IC50)
Molecular docking of flavonoids: Structures of selected flavonoids i.e., kaempferol, quercetin, apigenin, primuletin, catechin, hesperetin and naringenin (Table 1) were used as ligands for molecular docking to iNOS binding site. By using GADock method, the seven flavonoids were docked with iNOS and the binding affinity was characterized by binding energy (ΔG). Figure 3 shows the alignments of the binding conformations of the flavonoids to iNOS.
As shown in Fig. 4, there is a correlation between experimental values (expressed by IC50) and theoretical parameters (measured by binding energy), which justifies the present structural models and docking methods:
This correlation indicated that ΔG values calculated by GAdock method can be used to predict the iNOS inhibitory activities of quercetin derivatives.
||Structures quercetin derivatives, their binding energies and
predicted inhibitory activities
Predicting the affinities of quercetin derivatives to iNOS: Applying
the above equation, the predicted IC50 values of the quercetin derivatives
(Table 2) were calculated. Figure 5 showed
the interaction of 6, 8-dichloroquercetin-3-O-acetate to iNOS binding-site,
compare to that of quercetin, binding energy of quercetin-3-O-acetate,
6,8-dichloroquercetin-3-O-acetate and 6-bromoquercetin-3-O- acetate
were lower than that of quercetin, indicated that these compounds were proposed
to be more potent as iNOS inhibitor.
|| (a) Interaction of quercetin and (b) 6,8-dichloroquercetin-3-O-acetate
to iNOS binding site
|| Predictive absorption and distribution properties of quercetin
Prediction of absorption and distribution properties: Table 3 presented the values of predictive absorption and distribution of quercetin and its derivatives. Quercetin was predicted as moderately absorbed and low permeable compound, as well as strongly bound. These were not good properties for oral drug candidate. On the contrary, predictive absorption and distribution properties of some quercetin derivatives which proposed more potential as iNOS inhibitor than quercetin, i.e. quercetin-3-O-acetate, 6,8-dichloroquercetin-3-O-acetate and 6-bromoquercetin-3-O-acetat, generally were better than those of quercetin. Quercetin-3-O-acetate was predicted as well absorbed and weakly bound compound. In addition, 6,8-dichloroquercetin-3-O-acetate and 6-bromoquercetin-3-O-acetat were predicted as well absorbed and middle permeability compounds.
Prediction of interaction between 3D structure of protein and different ligands
by molecular docking helps researchers to find out important aspects such as
the active sites, binding energies, etc. This in silico technique is
very useful in the initial phase of drug discovery (Amir et
al., 2010). ArgusLab is one of computational software equipped with
two molecular docking tools, i.e. ArgusDock and GADock. Oda
et al. (2007) reported that GADock is superior in terms of accuracy
than ArgusDock. Our validation results based on the RMSD values also indicated
that GADock gave better accuracy than ArgusDock.
After being validated, GADock engine was used to conduct the molecular docking
between iNOS binding site and flavonoids. In general, the flavonoids consist
of 2 benzene rings (A and B), which are connected by an oxygen containing pyrane
ring (C). The X-ray structure of 3-bromo-7-nitroindazole, a known iNOS inhibitor,
shows that the aromatic ring of 3-bromo-7-nitroindazole binds to the heme pocket
of iNOS. In addition, the nitro moiety forms hydrogen bond with amide group
of Met368. Flavonoids could be docked similarly as 3-bromo-7-nitroindazole with
the planar region of A-ring of flavonoids oriented to the heme plane of iNOS.
According to Rosenfeld et al. (2002), when bound
to NOS, the planar system showed higher-affinity compared to the nonplanar system.
The carbonyl-groups of the flavonoids form hydrogen bond with amide groups of
Gly365 and Trp366.
Earlier study describing interaction of ligands to iNOS was reported by Francis
et al. (2008). It was reported that the active site of NOS consists
of four pockets, i.e. the substrate binding S pocket, the middle M pocket, the
C1 pocket and C2 pocket in the substrate access channels.
The residues Trp372 and Glu377 in the S pocket (iNOS) have been found to be
the main residues with which the substrates (L-arginin) form hydrogen bond.
Our results showed that the flavonoids form hydrogen bond with residues Gly365
and Trp366. However, there are clear structural differences between L-arginin
and flavonoids as ligands and hence lead to different amino acid residues of
iNOS taking part in the interaction.
Based on the study of interaction between flavonoids and iNOS binding site,
the affinity of quercetin derivatives on iNOS binding site was predicted. It
was obtained that energy binding values of quercetin-3-O-acetate, 6,8-dichloroquercetin-3-O-acetate
and 6-bromoquercetin-3-O-acetate were lower than that of quercetin, indicating
that these compounds have higher affinity on iNOS binding site than quercetin.
The iNOS inhibition properties of these compounds have not been reported. Most
publications (Hu and Kitts, 2004; Hamalainen
et al., 2007; Wan et al., 2009) reported
inhibitory effects of flavonoids on iNOS genetic expression instead of iNOS
inhibition properties of quercetin derivatives. The most relevant information
with our work was reported by Chen et al. (2001)
in which quercetin pentaacetate enhanced the iNOS activity to form Nitric Oxide
(NO), compared to quercetin.
Absorption and distribution, the part of pharmacokinetics, were considered
as important parameters to choose compounds as drug candidates. In this study,
three parameters from PreADMET program were calculated for quercetin and a set
quercetin derivatives. PreADMET featured prediction of absorption properties,
including Caco-2 cell permeability as well as percent human intestinal absorption
(%HIA). Caco-2 cell model is reliable in vitro models for the prediction
of oral drug absorption, while HIA is the sum of bioavailability and absorption
evaluated from ratio of excretion or cumulative excretion in urine, bile and
feces. For distribution properties, we used the calculation of predictive plasma
protein binding which available in PreADMET program. Only the unbound drug is
available for diffusion or transport across cell membranes and also for interaction
with a pharmacological target; therefore, plasma protein binding of a drug plays
an important role in drugs efficacy (Lee et al.,
Although, quercetin has been demonstrated to perform some beneficial biological
activities, the high-effective concentration and poor-absorptive properties
limited its practical applications. Gugler et al.
(1975) have studied the pharmacokinetic profile of quercetin. It was resulted
that after i.v. administration, the protein binding of quercetin was higher
than 98%. After oral administration no measurable plasma concentration of quercetin
could be detected, nor was found in urine, either in unchanged or as metabolized
form. It was proposed that the absorption of quercetin was very low. Our prediction
value of pharmacokinetic properties of quercetin calculated by PreADMET showed
the similar results. On the contrary, the pharmacokinetics profile of some quercetin
derivatives, including quercetin-3-O-acetate, 6,8-dichloroquercetin-3-O-acetate
and 6-bromoquercetin-3-O-acetate, were predicted to be better that of
quercetin. It was suggested that molecular modification by acetylation and halogenations
increased the lipophilicity of quercetin and furthermore enhanced its oral absorption.
In addition, these modifications also decrease the protein binding of quercetin.
Instead of ArgusDock, GAdock method was more suitable to predict the iNOS inhibitory activities of quercetin derivatives. By using GAdock method, computational docking of flavonoids to iNOS binding-site resulted to a correlation between experimental values (IC50) and theoretical parameters (binding energy). Quercetin-3-O-acetate, 6,8-dichloroquercetin-3-O-acetate and 6-bromoquercetin-3-O-acetat were proposed to be more potential as iNOS inhibitor than quercetin. The predictive absorption and distribution properties of these compounds i.e. human intestinal absorption, Caco-2 cell permeability and percent plasma protein binding were better than those of quercetin.
Amir, A., M.A. Siddiqui, N. Kapoor, A. Arya and H. Kumar, 2011. In silico molecular docking of influenza virus (PB2) protein to check the drug efficacy. Trends Bioinform., 4: 47-55.
ArgusLab 4.0.1, 2004. Planaria software LLC. Seattle.
Chen, Y., S. Shen, W. Lee, W. Hou, L. Yang and T.J.F. Lee, 2001. Inhibition of nitric oxide synthase inhibitors and lipopolysaccharide induced inducible NOS and cyclooxygenase-2 gene expressions by rutin, quercetin and quercetin pentaacetate in RAW 264,7 macrophage. J. Cell. Biochem., 82: 537-548.
Coskun, O., M. Kanter, F. Armutcu, K. Cetin, B. Kaybolmaz and O. Yazgan, 2004. Protective effects of quercetin, a flavonoid antioxidant, in absolute ethanol-induced acut gastric ulcer. Eur. J. Gen. Med., 1: 37-42.
Direct Link |
Francis, S.M., A. Mittal, M. Sharma and P.V. Bharatam, 2008. Design of Benzene-1,2-diamines as selective inducible nitric oxide synthase inhibitors: A combined de novo design and docking analysis. J. Mol. Model., 14: 215-224.
Gugler, R., M. Leschik and H.J. Dengler, 1975. Disposition of quercetin in man after single oral and intravenous doses. Eur. J. Clin. Pharm., 9: 229-234.
Hamalainen, M., R. Nieminen, P. Vuorela, M. Heinonen and E. Moilanen, 2007. Anti-inflammatory effects of flavonoids: Genistein, kaempferol, quercetin, and daidzein inhibits STAT-1 and NF-ΚB activation, whereas flavone, isorhamnetin, naringenin, and pelargonidin inhihibit only NF-ΚB activation along with their inhibitory effect on iNOS expression and NO production in activated macrophages. Mediators Inflamm., 2007: 1-10.
Hu, C. and D.D. Kitts, 2004. Luteolin and luteolin-7-O-glucoside from dandelion flower suppress iNOS and COX-2 in RAW264.7 cells. Mol. Cell. Biochem., 265: 107-113.
Ji, H.F. and H.Y. Zhang, 2006. Theoretical evaluation of flavonoids as multipotent agents to combat Alzheimer's disease. J. Mol. Struct. THEOCHEM, 767: 3-9.
Knowles, R.G. and S. Moncada, 1994. Nitric oxide synthasein mammals. Biochem. J., 298: 249-258.
Direct Link |
Korhonen, R., A. Lahti, H. Kankaanranta and E. Moilanen, 2005. Nitric oxide production and signaling in inflammation. Curr. Drug Targets Inflamm. Allergy, 4: 471-479.
Lee, S.K., I.H. Lee, H.J. Kim, G.S. Chang, J.E. Chung and K.T. No, 2003. The PreADME Approach: Web-Based Program for Rapid Prediction of Physico-Chemical, Drug Absorption and Drug-Like Properties. Blackwell Publishing, Massachusetts, pp: 418-420.
Morikawa, K., M. Nonaka, M. Narahara, I. Torii and K. Kawaguchi et al., 2003. Inhibitory effect of quercetin on carrageenan-induced inflammation in rats. Life Sci., 26: 709-721.
Morris, G.M. and M. Lim-Wilby, 2008. Molecular Docking, Methods in Molecular Biology. In: Molecular Modeling of Proteins, Kukol, A. (Ed.). Humana Press, Totowa, New Jersey, pp: 365-382.
Oda, A. and O. Takahashi, 2009. Validation of arguslab efficiencies for binding free energy calculations. Chem-Bio. Informatics J., 9: 52-61.
Oda, A., M. Okayasu, Y. Kamiyama, T. Yoshida, O. Takahashi and H. Matsuzaki, 2007. Evaluation of docking accuracy and investigastions of roles of parameters and each term in scoring functions for protein-ligand docking using arguslab software. Bull. Chem. Soc. Jap., 80: 1920-1925.
Olszanecki, R., A. Gebska, V.I. Kozlovski and R.J. Gryglewski, 2002. Flavonoids and nitric oxide synthase. J. Physiol. Pharmacol., 53: 571-584.
Direct Link |
Peng, Y., Z. Deng and C. Whang, 2008. Preparation and prodrug studies of quercetin pentabenzensulfonate. Yakugaku Zasshi, 128: 1845-1849.
Direct Link |
Rosenfeld, R.J., E.D. Garcin, K. Panda, G. Andersson and A. Aberg et al., 2002. Conformational changes in nitric oxide synthases induced by chlorzoxazone and nitroindazoles: Crystallographic and computational analyses of inhibitor potency. Biochemistry, 41: 13915-13925.
Wan, L.L., J. Xia, D. Ye, J. Liu, J. Chen and G. Wang, 2009. Effects of quercetin on gene and protein expression of NOX and NOS after myocardial ischemia and reperfusion in rabbit. Cardiovasc. Ther., 27: 28-33.
Zheng, M., Z. Zhang, W. Zhu, H. Liu, X. Luo, K. Chen and H. Jiang, 2006. Essential structural profile of a dual functional inhibitor against cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX): Molecular docking and 3D-QSAR analyses on DHDMBF analogues. Bioorganic Med. Chem., 14: 3428-3437.